Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
IPO Year: 2014
Exchange: NASDAQ
Website: revance.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $16.00 → $9.00 | Buy → Neutral | Mizuho |
| 1/9/2024 | $30.00 → $8.00 | Buy → Neutral | Goldman |
| 8/16/2023 | $20.00 | Underperform → Neutral | Exane BNP Paribas |
| 10/11/2022 | $27.00 | Equal-Weight | Morgan Stanley |
| 9/22/2022 | $33.00 | Buy | Goldman |
| 10/26/2021 | $33.00 → $22.00 | Overweight | Barclays |
| 10/25/2021 | $17.00 | Overweight → Equal-Weight | Wells Fargo |
| 10/18/2021 | $45.00 → $25.00 | Buy | Needham |
| 10/18/2021 | $26.00 → $18.00 | Buy | HC Wainwright & Co. |
| 10/13/2021 | $35.00 → $26.00 | Buy | HC Wainwright & Co. |
Fastest customizable press release news feed in the world
Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207314086/en/ Jeff Bedard, Founder and Chief Executive Officer of Crown commented, "We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and en
The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The Offer and the Merger Crown's tender offer to acquire all of
JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance at a purchase price of $3.65 per Share, net to the stockholder in cash without interest and less any required tax withholding (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 and was not extended (such date and time, the "Expiration Time").
Crown offer of $3.65 per share is the only offer available to Revance stockholdersCrown offer unanimously approved by the Revance Board of DirectorsTeoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today reminded Revance stockholders of the recommendation to tender their shares in support of Crown's cash tender offer (the "tender offer") to acquire all of the issued and outstanding shares of
Increased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025 Crown's offer is the only fully-financed offer currently available to Revance's stockholders Outside termination date under the A&R Merger Agreement is February 7, 2025 Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the "Second Amendment," together with the Amended and Restated Merger Agreement, da
JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ:RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire o
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ:RVNC) to acquire Revance for $3.60 per share in cash. Teoxane beneficially owns 6.2% of the outstanding shares of common stock of Revance. Teoxane's proposal provides a 16% premium over the $3.10 per share price in Revance's amended and restated merger agreement with Crown Laboratories, Inc. ("Crown"), as announced on December 9, 2024. Teoxane believes its proposal is a superior alternative to the amend
Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (NASDAQ:RVNC) at a price of $3.10 per share in cash. The tender offer is being made in connection with the Amended and Restated Merger Agreement, dated December 7, 2024 (as amended or supplemented from time to time, the "A&R Merger Agreement").
Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merger agreement entered into by the parties on August 11, 2024, pursuant to which the companies will seek to merge the two organizations. Under the terms of the amended and restated merger agreement, which has been unanimously approved by Revance's Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance's com
Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the st
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Mizuho downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $9.00 from $16.00 previously
Goldman downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $8.00 from $30.00 previously
Exane BNP Paribas upgraded Revance Therapeutics from Underperform to Neutral and set a new price target of $20.00
Morgan Stanley initiated coverage of Revance Therapeutics with a rating of Equal-Weight and set a new price target of $27.00
Goldman initiated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $33.00
Barclays reiterated coverage of Revance Therapeutics with a rating of Overweight and set a new price target of $22.00 from $33.00 previously
Wells Fargo downgraded Revance Therapeutics from Overweight to Equal-Weight and set a new price target of $17.00
Needham reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $25.00 from $45.00 previously
HC Wainwright & Co. reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $18.00 from $26.00 previously
HC Wainwright & Co. reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $26.00 from $35.00 previously
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
15-12G - Revance Therapeutics, Inc. (0001479290) (Filer)
SCHEDULE 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)
Live Leadership Updates
EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company. "We're excited to announce Aubrey Rankin's appointment to Nanostics' Board of Directors. Aubrey's vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®," said
- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD's processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end - Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection - Conference call and webcast today at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Financial Highlights Revenue for the first quarter 2021 totaled $
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Financial Highlights Revenue for the fourth quarter and full year ended December 31, 2020 was $11.1 million and $15.3 million compared to $0.1 million and $0.4 million for the same periods in 2019, respectively. The increase was primarily due to the commercial launch of the RHA® Collection of dermal fillers and the HintMD fintech platform. Revenue for the fourth quarter included $10.0 million of
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware, and fintech and payments thought leader and entrepreneur, Carey O’Connor Kolaja, to its Board of Directors. The appointments will be made effective on March 1, 2021 for Ms. Kolaja and March 6, 2021, for Ms. Ware. “As we continue to grow and evolve our company strategy, it is critical that we expand the focus and expertise of our board. Olivia’s extensive background in drug portfolio and program management and Carey’s deep
This live feed shows all institutional transactions in real time.
Live finance-specific insights
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The Offer and the Merger Crown's tender offer to acquire all of
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.
Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the com
Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S. and Canadian callers, and reference conference ID 509643 or from the webcast link in the investor relations section of the company's website at: www.revance.com. A webc
Conference Call Scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (888) 330-3637 for U.S. and Canadian callers, and reference conference ID 5680588 or from the webcast link in the investor relations section of the company's website at: www.revance.com. A webcast
Conference Call Scheduled for Tuesday, May 9, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and reference conference ID: 7745325, or from the webcast link in the investor relations section of the company's website at:
Conference Call Scheduled for Tuesday, February 28, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 and reference conference ID: 1286316, or from the webcast link in the investor relations section of the company's website at: www.revance.com. A replay of the call w
Conference Call Scheduled for Tuesday, November 8, 2022 at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter 2022 financial results on Tuesday, November 8, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial
Conference Call Scheduled for Tuesday, August 9, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website